Svendsen E, Karwinski B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol. 1989;42(8):805-9. [https://doi.org/10.1136/jcp.42.8.805]. [PMID:2475526]

Satoh T, Oki A, Uno K, et al. High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer. 2007;97(8):1053-7. [https://doi.org/10.1038/sj.bjc.6603989]. [PMID:17895896]

Abu Saadeh F, Norris L, O’Toole S, et al. Tumour expression of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk. Thromb Res. 2013;132(5):627-34. [https://doi.org/10.1016/j.thromres.2013.09.016]. [PMID:24094893]

Zhang Y, Yang JX, Wu M, Shen K. Clinicopathological conference: an advanced ovarian carcinoma patient suddenly died of pulmonary embolism. Zhongguo Yi. Xue Ke Yuan Xue Bao. 2003;25:471-5.

Shiota M, Kotani Y, Umemoto M, et al. Risk factors for deep-vein thrombosis and pulmonary thromboembolism in benign ovarian tumor. Tohoku J Exp Med. 2011;225(1):1-3. [https://doi.org/10.1620/tjem.225.1]. [PMID:21817850]

Rodriguez AO, Wun T, Chew H, Zhou H, Harvey D, White RH. Venous thromboembolism in ovarian cancer. Gynecol Oncol. 2007;105(3):784-90. [https://doi.org/10.1016/j.ygyno.2007.02.024]. [PMID:17408726]

Pineo GF, Brain HC, Gallus AS, Hirsh J, Hatton MW, Regoeczi E. Tumors, mucus production, and hypercoagulability. Am NY Acad Sci. 1974;230(1):262-70. [https://doi.org/10.1111/j.1749-6632.1974.tb14458.x]. [PMID:4522873]

Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using medicare claims data. Medicine. 1999;78(5):285-91. [https://doi.org/10.1097/00005792-199909000-00001]. [PMID:10499070]

Boger-Megiddo I, Weiss NS. Histologic subtypes and laterality of primary epithelial ovarian tumors. Gynecol Oncol. 2005;97(1):80-3. [https://doi.org/10.1016/j.ygyno.2004.11.054]. [PMID:15790441]

Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: WHO Press; 2014.

Ayhan A, Guvendag Guven ES, Guven S, Kucukali T. Recurrence and prognostic factors in borderline ovarian tumors. Gynecol Oncol. 2005;98(3):439-45. [https://doi.org/10.1016/j.ygyno.2005.05.033]. [PMID:16009407]

Jetley S, Khetrapal S, Ahmad A, Jairajpuri ZS. Atypical proliferative endometrioid tumor of ovary: report of a rare case. J Postgrad Med. 2016;62(2):129-32. [https://doi.org/10.4103/0022-3859.168092]. [PMID:26497398]

Janssen W. Forensic histopathology. Berlin: Springer; 1977.

Trousseau A. Clinique médicale de l’Hôtel-Dieu de Paris. Paris: JB Bailliere et Fils; 1865.

Gunderson CC, Thomas ED, Slaughter KN, et al. The survival detriment of venous thromboembolism with epithelial ovarian cancer. Gynecol Oncol. 2014;134(1):73-7. [https://doi.org/10.1016/j.ygyno.2014.04.046]. [PMID:24793732]

Heath OM, van Beekhuizen HJ, Nama V, et al. Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases. Thromb Res. 2016;137:30-5. [https://doi.org/10.1016/j.thromres.2015.11.030]. [PMID:26653367]

Ikushima S, Ono R, Fukuda K, Sakayori M, Awano N, Kondo K. Trousseau’s syndrome: cancer-associated thrombosis. Jpn J Clin Oncol. 2016;46(3):204-8. [https://doi.org/10.1093/jjco/hyv165]. [PMID:26546690]

Lee AY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006;24(9):1404-8. [https://doi.org/10.1200/JCO.2005.03.5600]. [PMID:16549834]

Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4(6):465-73. [https://doi.org/10.1038/sj.neo.7900263]. [PMID:12407439]

Dvorak HF. Thrombosis and cancer. Hum Pathol. 1987;18(3):275-84. [https://doi.org/10.1016/S0046-8177(87)80010-2]. [PMID:3546076]

Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood. 1983;62(1):14-31. [PMID:6407544]

Belt RJ, Leite C, Haas CD, Stephens RL. Incidence of hemorrhagic complications in patients with cancer. JAMA. 1978;239(24):2571-4. [https://doi.org/10.1001/jama.239.24.2571]. [PMID:660790]

Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339-46. [https://doi.org/10.1002/cncr.23062]. [PMID:17918266]

Bakhru A. Effect of ovarian tumor characteristics on venous thromboembolic risk. J Gynecol Oncol. 2013;24(1):52-8. [https://doi.org/10.3802/jgo.2013.24.1.52]. [PMID:23346314]

Poller L. Oral contraceptives, blood clotting and thrombosis. Br Med Bull. 1978;34(2):151-6. [https://doi.org/10.1093/oxfordjournals.bmb.a071485]. [PMID:350338]

Uno K, Homma S, Satoh T, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 2007;96(2):290-5. [https://doi.org/10.1038/sj.bjc.6603552]. [PMID:17211468]

Molnar S, Guglielmone H, Lavarda M, Rizzi ML, Jarchum G. Procoagulant factors in patients with cancer. Hematology. 2007;12(6):555-9. [https://doi.org/10.1080/10245330701521416]. [PMID:17852460]

De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol. 2004;50(3):187-96. [https://doi.org/10.1016/j.critrevonc.2003.10.003]. [PMID:15182825]

Kurman RJ. Blaustein’s Pathology of the female genital tract. 5th ed. New York: Springer; 2001. p. 791-904.

Srettabunjong S. Systemic thromboembolism after deep vein thrombosis caused by uterine myomas. Am J Forensic Med Pathol. 2013;34(3):207-9. [https://doi.org/10.1097/PAF.0b013e318298a456]. [PMID:23835533]

Srettabunjong S, Chuangsuwanich T. Inferior vena cava tumor thrombosis secondary to metastatic uterine cancer: a rare cause of sudden unexpected death. J Forensic Sci. 2016;61(2):555-8. [https://doi.org/10.1111/1556-4029.13032]. [PMID:27404631]